SYNLIFE INC
Liposomal encapsulated enzyme formulation that rapidly degrades ethanol in blood to treat alcohol poisoning
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2016
- Latest Form D
- $500K, Jul 2018
- Total capital
- $796K
- Federal grants
- $296K
- 1 award · 2021
- At sector median 1 award
- Private capital raised
- $500K
- 1 Form D · last Jul 2018
- 99 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 8 pending · first 2023
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · A Liposomal Enzyme System for Removal of Ethanol from the Blood$296K
- Private capital raisedForm D · SEC · 1st filing$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing in Biotech · 4373 companies
Line = median- Federal contractsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Tamar ErdfarbExecutive OfficerNamed in SEC Form D filings
- Jeremy WertheimerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 9- PendingMicroparticle-based Enzyme Systems For Selective Removal Of Target MoleculesUSPTOApplication 18225323
- GrantedMicroparticle-based Enzyme Systems For Selective Removal Of Target MoleculesUSPTOUS 11,723,958
- PendingCompositions And Methods For The In Situ Delivery Of Therapeutic And Diagnostic AgentsUSPTOApplication 17279069
Show all 9 patent records
- Microparticle-based Enzyme Systems For Selective Removal Of Target MoleculesNov 16, 2023 · Application 18225323Pending
- Microparticle-based Enzyme Systems For Selective Removal Of Target MoleculesAug 15, 2023 · US 11,723,958Granted
- Compositions And Methods For The In Situ Delivery Of Therapeutic And Diagnostic AgentsFeb 17, 2022 · Application 17279069Pending
- Liposomal Methods For Purification Of ProteinsOct 10, 2019 · Application 16377989Pending
- Compositions And Methods For The In Situ Delivery Of Therapeutic AgentsApplication 62735608Pending
- Liposomal Methods For Purification Of ProteinsApplication 62653742Pending
- Microparticle-based Enzyme Systems For Selective Removal Of Target MoleculesApplication PCTUS2021012599Pending
- Nanoparticle-encapsulated Enzyme Systems For Selective Removal Of Target MoleculesApplication 62958935Pending
- Compositions And Methods For The In Situ Delivery Of Therapeutic And Diagnostic AgentsApplication PCTUS2019052467Pending
Related companies, and why
- WinSanTor, Inc.Similar federal contract value in Biotech · null in contracts
- Kioga Inc.Similar federal contract value in Biotech · null in contracts
- ZENA THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- KINARX, INCSimilar federal contract value in Biotech · null in contracts
- KNOUBIS BIO, INC.Similar federal contract value in Biotech · null in contracts
- EPIC NUTRITION FOR Y LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .